Biocon Ltd Board Approves Final Dividend, Major Acquisition of BBL Equity, and Leadership Changes

Biocon Ltd Board Approves Final Dividend, Major Acquisition of BBL Equity, and Leadership Changes​

Biocon Limited announced that its Board of Directors held a meeting on May 07, 2026, approving several key corporate actions, including the final dividend recommendation, the audited financial results for the year ended March 31, 2026, and a significant acquisition of Biocon Biologics Limited (BBL) equity shares.

The company also approved changes to its statutory auditors, the designation of senior management personnel, and the appointment of new independent directors, aiming to facilitate the integration of BBL into a unified global biopharmaceutical leader.

Financial Results and Dividend Recommendation​

The Board approved the audited financial results, both standalone and consolidated, for the quarter and financial year ending March 31, 2026.

Furthermore, the company recommended a final dividend at a rate of 10% or Re. 0.50 per equity share, based on the face value of Rs. 5 each, for the financial year ended March 31, 2026.

The company fixed Friday, July 03, 2026, as the record date for determining shareholder entitlement to the final dividend. The dividend is scheduled to be paid on or before August 31, 2026, subject to the approval of shareholders at the ensuing Annual General Meeting (AGM).

Governance and Leadership Appointments​

Several key governance changes were approved by the Board:

Statutory Auditors:
The Board recommended the appointment of M/s. S. R. Batliboi & Associates LLP, Chartered Accountants, as the Statutory Auditors for a term of five (five) consecutive years. The tenure is set to commence from the conclusion of the ensuing 48th AGM till the conclusion of the 53rd AGM. This appointment replaces the retiring Statutory Auditors, M/s. B S R & Co. LLP, Chartered Accountants.

Senior Management Personnel:
Based on the recommendation of the Nomination and Remuneration Committee (NRC), the Board approved the designation of two individuals as Senior Management Personnel with immediate effect:

• Dr. Anuj Goel, Chief Development Officer.
• Mr. Susheel Umesh, Chief Commercial Officer -Emerging Markets and Head of Global API & Global BD.

Director Changes:
The Board approved several director changes:

• Re-appointment: Ms. Rekha Mehrotra Menon was approved for a second term of five (five) consecutive years as an Independent Director, commencing from the date of the ensuing AGM (August 06, 2026) till August 05, 2031, subject to shareholder approval through Postal Ballot.
• New Appointments: Five independent directors were recommended for appointment, effective from August 01, 2026, till the conclusion of the 50th AGM (2028). These include Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai.
• Non-Executive Director: The appointment of Mr. Thomas Jason Roberts as a Non-Executive Non-Independent Director was also recommended, effective from August 01, 2026, and liable to retire by rotation.

Strategic Acquisition of Biocon Biologics Limited (BBL)​

The Board provided detailed approval for the acquisition of equity shares of BBL by the Company through a multi-pronged transaction structure, aiming to integrate BBL as a wholly owned subsidiary.

The proposed transaction involves acquiring up to 1,15,36,956 shares of BBL from Selling Shareholders/Proposed Allottees for a consideration other than cash. This consideration will be discharged through the issuance and allotment of up to 87,92,317 equity shares of Biocon Limited, having a face value of Rs. 5 each, on a preferential basis.

Key Financial Details of the Acquisition:

• Total Acquisition Consideration: Up to Rs. 330.73 Crores (Rupees Three Hundred and Thirty Crore and Seventy Three Lakhs Only).
• Issue Price: Rs. 376.16 per share, including a premium of Rs. 371.16 per share.

The acquisition structure covers three parts:

1. Sale Shares Acquisition (Preferential Issue): The Company acquires shares from 102 selling shareholders, with the total consideration amounting to Rs. 330.73 Crores.
2. OCD Conversion: The Board approved the conversion of 1,125 Optionally Convertible Debentures (OCDs) of BBL into 4,11,11,689 equity shares of BBL, of face value Rs. 10 each.
3. CCD Conversion: Similarly, the Board approved the conversion of 1,06,86,044 Compulsorily Convertible Debentures (CCDs) of BBL into 1,06,86,044 equity shares of BBL, of face value Rs. 10 each.

Other Corporate Approvals and Future Plans​

• Long-Term Incentive Plan: The Board approved the formulation and adoption of the Biocon Unity Long Term Incentive Plan 2026, along with various supporting plans (PSU, RSU, Employee Stock Purchase, and Management Stock Unit Plan 2026).
• Annual General Meeting (AGM): The 48th AGM of the Members of the Company is scheduled for Thursday, August 06, 2026, via Video Conferencing/Other AudioVisual Means.

For reference, the detailed financial results, including standalone and consolidated statements, and the comprehensive list of selling shareholders involved in the preferential issue are appended to the announcement.

BIOCON Stock Price Movement​

Shares of Biocon Limited are edging higher to ₹391.75 as of 11:51 AM today, capitalizing on a ₹9.50 jump, or 2.49%. The rally is underpinned by significant trading activity, with 3.76 million shares traded so far in the live market.